Certain cancers stem from mutations that prevent a cell from repairing its damaged DNA efficiently. But antitumour chemotherapy that exploits that repair defect can in turn be nullified by counter-mutation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
Journal of Ovarian Research Open Access 21 June 2021
-
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
Breast Cancer Research Open Access 05 March 2010
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Edwards, S. L. et al. Nature 451, 1111–1115 (2008).
Sakai, W. et al. Nature 451, 1116–1120 (2008).
Bryant, H. E. et al. Nature 434, 913–917 (2005).
Farmer, H. et al. Nature 434, 917–921 (2005).
Nagrath, S. et al. Nature 450, 1235–1239 (2007).
Furuta, S. et al. Cancer Cell 10, 13–24 (2006).
Kinzler, K. W. & Vogelstein, B. Nature 386, 761–763 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Livingston, D., Silver, D. Crossing over to drug resistance. Nature 451, 1066–1067 (2008). https://doi.org/10.1038/4511066a
Published:
Issue Date:
DOI: https://doi.org/10.1038/4511066a
This article is cited by
-
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
Journal of Ovarian Research (2021)
-
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
Breast Cancer Research (2010)
-
Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer
Nature Reviews Clinical Oncology (2009)